Shanghai-Hong Kong Zhongke

Shanghai-Hong Kong Zhongke International Biotechnology Co., Ltd. (ZSHK Laboratories) operates as a preclinical contract research organization (CRO) servicing the biopharmaceutical industry. Founded in 2019, the company is headquartered in Hong Kong with its origins tracing back to the Safety Assessment and Research Center of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The core team possesses over two decades of experience in drug safety evaluation.

The company's business model is centered on providing a comprehensive, one-stop platform for preclinical research and development services to a global client base of pharmaceutical companies and R&D institutions. This service-based revenue model encompasses a suite of offerings critical for drug and medical device development. Key services include pharmacology and pharmacodynamics research, drug metabolism and pharmacokinetic (DMPK) studies, and comprehensive safety evaluations. By managing these essential preclinical stages, ZSHK enables its clients to advance their products through the regulatory pipeline.

ZSHK has established a significant operational footprint with independent laboratory facilities in strategic locations, including the Hong Kong Science Park, Pingshan District in Shenzhen, and the Suzhou Industrial Park in Jiangsu. This network of labs is complemented by a strategic focus on the supply chain for research models; the company has developed breeding and research bases for experimental canines and non-human primates in Hunan and Guangxi. The company has received multiple rounds of venture capital funding, including a Series B round in November 2022, to support its expansion.

The firm's service portfolio is extensive, covering early screening, pharmacodynamics, pharmacokinetics, and toxicity prediction. It offers specialized services such as histopathology research and laboratory testing and analysis. ZSHK also provides robust support platforms, including advanced IT and computerized systems designed for data security, a comprehensive instrument management system compliant with international regulations (NMPA, OECD, FDA), and a sophisticated document management system to support multinational applications. A subsidiary, AnLing Biomed (Shenzhen) Co., Ltd., achieved GLP certification from the NMPA in April 2023, a key milestone indicating adherence to quality standards for non-clinical laboratory studies.

Keywords: preclinical CRO, biopharmaceutical services, drug development, medical device testing, pharmacology, pharmacodynamics, DMPK, toxicology, safety evaluation, contract research organization, clinical trial support, laboratory services, animal models, non-human primates, GLP certification, drug safety testing, biopharmaceutical outsourcing, preclinical studies, pharmaceutical R&D, life sciences, biotechnology services, Shenzhen, Suzhou, Hong Kong